Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

Intellia expects to present additional data from the ongoing Phase 1/2 study in the second half of 2025. The Company is on track to submit a Biologics License Application (BLA) in the second half of ...

Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease ...

The competitive landscape of the ARMD market in 2025 is dominated by a few key players and a leading product. Eylea, a therapy for age-related molecular degeneration, is projected to command a ...

Regeneron Pharmaceuticals, Inc. saw a significant boost in ownership by Raiffeisen Bank International AG. The bank now ...

The demand for renal transplant therapeutics is increasing due to several important factors. Chief among these is the global rise in kidney transplan ...

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.